AMRI
Income statement / Annual
Last year (2016), Albany Molecular Research, Inc.'s total revenue was $570.45 M,
an increase of 41.78% from the previous year.
In 2016, Albany Molecular Research, Inc.'s net income was -$70.17 M.
See Albany Molecular Research, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
FY-2011
|
FY-2010
|
FY-2009
|
FY-2008
|
FY-2007
|
| Period Ended |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
12/31/2011 |
12/31/2010 |
12/31/2009 |
12/31/2008 |
12/31/2007 |
| Operating Revenue |
$570.45 M |
$402.36 M |
$276.57 M |
$246.58 M |
$226.69 M |
$207.65 M |
$198.07 M |
$196.42 M |
$229.26 M |
$192.51 M |
| Cost of Revenue |
$437.65 M
|
$295.53 M
|
$209.19 M
|
$171.92 M
|
$168.06 M
|
$168.47 M
|
$152.67 M
|
$138.74 M
|
$146.08 M
|
$264.06 M
|
| Gross Profit |
$132.80 M
|
$106.83 M
|
$67.38 M
|
$74.65 M
|
$58.62 M
|
$39.18 M
|
$45.39 M
|
$57.68 M
|
$83.19 M
|
-$71.55 M
|
| Gross Profit Ratio |
0.23
|
0.27
|
0.24
|
0.3
|
0.26
|
0.19
|
0.23
|
0.29
|
0.36
|
-0.37
|
| Research and Development Expenses |
$16.05 M
|
$5.47 M
|
$1.00 M
|
$414.00 K
|
$906.00 K
|
$7.94 M
|
$11.09 M
|
$14.55 M
|
$13.13 M
|
$12.82 M
|
| General & Administrative Expenses |
$122.14 M
|
$77.39 M
|
$48.90 M
|
$42.26 M
|
$40.90 M
|
$41.07 M
|
$42.40 M
|
$38.19 M
|
$39.36 M
|
$33.25 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$122.14 M
|
$77.39 M
|
$48.90 M
|
$42.26 M
|
$40.90 M
|
$41.07 M
|
$42.40 M
|
$38.19 M
|
$39.36 M
|
$33.25 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$138.18 M
|
$82.87 M
|
$49.90 M
|
$42.67 M
|
$41.81 M
|
$49.01 M
|
$53.49 M
|
$52.74 M
|
$52.49 M
|
$46.07 M
|
| Cost And Expenses |
$589.21 M
|
$388.71 M
|
$270.85 M
|
$226.40 M
|
$225.98 M
|
$243.78 M
|
$270.22 M
|
$218.30 M
|
$203.30 M
|
$181.16 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$39.92 M
|
$19.35 M
|
$10.96 M
|
$1.26 M
|
$0.00
|
$714.00 K
|
$175.00 K
|
$270.00 K
|
$493.00 K
|
$853.00 K
|
| Depreciation & Amortization |
$56.71 M
|
$29.52 M
|
$14.13 M
|
$15.34 M
|
$17.33 M
|
$18.16 M
|
$17.10 M
|
$16.82 M
|
$17.78 M
|
$16.82 M
|
| EBITDA |
$36.67 M |
$45.40 M |
$19.62 M |
$36.30 M |
$17.45 M |
-$17.77 M |
-$55.57 M |
-$4.96 M |
$46.17 M |
$32.05 M |
| EBITDA Ratio |
0.06
|
0.11
|
0.07
|
0.15
|
0.08
|
-0.09
|
-0.28
|
-0.03
|
0.2
|
0.17
|
| Operating Income Ratio |
-0.03
|
0.03
|
0.02
|
0.08
|
0
|
-0.17
|
-0.36
|
-0.11
|
0.11
|
0.06
|
| Total Other Income/Expenses Net |
-$41.20 M
|
-$17.12 M
|
-$11.19 M
|
-$472.00 K
|
-$584.00 K
|
-$506.00 K
|
-$685.00 K
|
-$169.00 K
|
$1.93 M
|
$3.03 M
|
| Income Before Tax |
-$59.96 M
|
-$3.47 M
|
-$5.47 M
|
$19.70 M
|
$119.00 K
|
-$36.64 M
|
-$72.84 M
|
-$22.05 M
|
$27.89 M
|
$14.39 M
|
| Income Before Tax Ratio |
-0.11
|
-0.01
|
-0.02
|
0.08
|
0
|
-0.18
|
-0.37
|
-0.11
|
0.12
|
0.07
|
| Income Tax Expense |
$10.21 M
|
-$1.17 M
|
-$2.19 M
|
$7.02 M
|
$3.90 M
|
-$4.34 M
|
-$9.97 M
|
-$5.36 M
|
$7.33 M
|
$5.45 M
|
| Net Income |
-$70.17 M
|
-$2.30 M
|
-$3.28 M
|
$12.68 M
|
-$3.78 M
|
-$32.30 M
|
-$62.87 M
|
-$16.70 M
|
$20.56 M
|
$8.94 M
|
| Net Income Ratio |
-0.12
|
-0.01
|
-0.01
|
0.05
|
-0.02
|
-0.16
|
-0.32
|
-0.08
|
0.09
|
0.05
|
| EPS |
-1.65 |
-0.0694 |
-0.1 |
0.41 |
-0.13 |
-1.07 |
-2.05 |
-0.54 |
0.66 |
0.28 |
| EPS Diluted |
-1.65 |
-0.0694 |
-0.1 |
0.4 |
-0.13 |
-1.07 |
-2.05 |
-0.54 |
0.66 |
0.28 |
| Weighted Average Shares Out |
$42.45 M
|
$33.17 M
|
$31.53 M
|
$31.07 M
|
$29.77 M
|
$30.20 M
|
$30.67 M
|
$30.92 M
|
$31.15 M
|
$31.91 M
|
| Weighted Average Shares Out Diluted |
$42.45 M
|
$33.17 M
|
$31.53 M
|
$32.04 M
|
$29.77 M
|
$30.20 M
|
$30.67 M
|
$30.92 M
|
$31.15 M
|
$31.91 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
